QUARTERLY REPORT

Q3 2025 — Form 10-Q

Q3 2025PDF · 38 pages509 KB
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2025
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from 	to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation 	I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class 	Trading Symbol(s) 	Name of Each Exchange on Which Registered
Common Shares, Without Par Value 	ABT 	New York Stock Exchange
NYSE Texas
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer  	Accelerated Filer 
Non-Accelerated Filer  	Smaller reporting company 
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 
As of September 30, 2025, Abbott Laboratories had 1,738,871,947 common shares without par value outstanding.

-- 1 of 38 --

Table of Contents
Abbott Laboratories
Table of Contents
Part I - Financial Information
Page
Item 1. Financial Statements and Supplementary Data
Condensed Consolidated Statement of Earnings 	3
Condensed Consolidated Statement of Comprehensive Income 	4
Condensed Consolidated Balance Sheet 	5
Condensed Consolidated Statement of Shareholders’ Investment 	6
Condensed Consolidated Statement of Cash Flows 	8
Notes to the Condensed Consolidated Financial Statements 	9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 	25
Item 4. Controls and Procedures 	31
Part II - Other Information 	31
Item 1. Legal Proceedings 	31
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 	32
Item 6. Exhibits 	33
Signature 	34
2

-- 2 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended 	Nine Months Ended
September 30 	September 30
2025 	2024 	2025 	2024
Net sales 	$ 	11,369 $ 	10,635 $ 	32,869 $ 	30,976
Cost of products sold, excluding amortization of intangible assets 	5,075 	4,698 	14,397 	13,764
Amortization of intangible assets 	420 	470 	1,260 	1,413
Research and development 	766 	713 	2,207 	2,095
Selling, general and administrative 	3,051 	2,895 	9,203 	8,790
Total operating cost and expenses 	9,312 	8,776 	27,067 	26,062
Operating earnings 	2,057 	1,859 	5,802 	4,914
Interest expense 	121 	142 	373 	423
Interest (income) 	(77) 	(91) 	(230) 	(253)
Net foreign exchange (gain) loss 	(17) 	(11) 	(35) 	(17)
Other (income) expense, net 	(150) 	(121) 	(414) 	(222)
Earnings before taxes 	2,180 	1,940 	6,108 	4,983
Taxes on earnings 	536 	294 	1,360 	810
Net Earnings 	$ 	1,644 $ 	1,646 $ 	4,748 $ 	4,173
Basic Earnings Per Common Share 	$ 	0.94 $ 	0.94 $ 	2.72 $ 	2.39
Diluted Earnings Per Common Share 	$ 	0.94 $ 	0.94 $ 	2.70 $ 	2.38
Average Number of Common Shares Outstanding Used for Basic Earnings Per
Common Share 	1,742,142 	1,739,466 	1,741,617 	1,740,869
Dilutive Common Stock Options 	7,219 	8,131 	7,544 	8,565
Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options 	1,749,361 	1,747,597 	1,749,161 	1,749,434
Outstanding Common Stock Options Having No Dilutive Effect 	1,443 	6,905 	1,431 	6,892
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3

-- 3 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months Ended 	Nine Months Ended
September 30 	September 30
2025 	2024 	2025 	2024
Net Earnings 	$ 	1,644 $ 	1,646 $ 	4,748 $ 	4,173
Foreign currency translation gain (loss) adjustments, net of taxes of $(6) and $52
in 2025 and $— and $— in 2024 	(136) 	497 	1,414 	75
Net actuarial gains (losses) and amortization of net actuarial losses and prior
service costs and credits, net of taxes of $—and $— in 2025 and $— and $1 in
2024 	(11) 	14 	45 	25
Net gains (losses) for derivative instruments designated as cash flow hedges, net
of taxes of $8 and $(101) in 2025 and $(63) and $(6) in 2024 	39 	(180) 	(237) 	(65)
Other comprehensive income (loss) 	(108) 	331 	1,222 	35
Comprehensive Income 	$ 	1,536 $ 	1,977 $ 	5,970 $ 	4,208
September 30,
2025 December 31,
2024
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments 	$ 	(6,091) $ 	(7,505)
Net actuarial (losses) and prior service (costs) and credits 	(566) 	(611)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges 	(27) 	210
Accumulated other comprehensive income (loss) 	$ 	(6,684) $ 	(7,906)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4

-- 4 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
September 30,
2025
December 31,
2024
Assets
Current Assets:
Cash and cash equivalents 	$ 	7,511 $ 	7,616
Short-term investments 	222 	351
Trade receivables, less allowances of $490 in 2025 and $439 in 2024 	8,138 	6,925
Inventories:
Finished products 	4,130 	3,700
Work in process 	961 	840
Materials 	1,617 	1,654
Total inventories 	6,708 	6,194
Prepaid expenses and other receivables 	2,260 	2,570
Total Current Assets 	24,839 	23,656
Investments 	951 	886
Property and equipment, at cost 	24,816 	22,740
Less: accumulated depreciation and amortization 	13,312 	12,082
Net property and equipment 	11,504 	10,658
Intangible assets, net of amortization 	5,598 	6,647
Goodwill 	23,971 	23,108
Deferred income taxes and other assets 	17,318 	16,459
$ 	84,181 $ 	81,414
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable 	$ 	4,123 $ 	4,195
Salaries, wages and commissions 	1,735 	1,701
Other accrued liabilities 	5,880 	5,143
Dividends payable 	1,030 	1,024
Income taxes payable 	469 	594
Current portion of long-term debt 	1,345 	1,500
Total Current Liabilities 	14,582 	14,157
Long-term debt 	11,596 	12,625
Post-employment obligations, deferred income taxes and other long-term liabilities 	6,739 	6,731
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2025: 1,996,743,794; 2024: 1,991,472,630 	25,412 	25,153
Common shares held in treasury, at cost — Shares: 2025: 257,871,122; 2024: 259,774,639 	(16,877) 	(16,844)
Earnings employed in the business 	49,103 	47,261
Accumulated other comprehensive income (loss) 	(6,684) 	(7,906)
Total Abbott Shareholders’ Investment 	50,954 	47,664
Noncontrolling interests 	310 	237
Total Shareholders’ Investment 	51,264 	47,901
$ 	84,181 $ 	81,414
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5

-- 5 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended September 30
2025 	2024
Common Shares:
Balance at June 30
Shares: 2025: 1,996,448,469; 2024: 1,990,029,292 	$ 	25,284 $ 	24,858
Issued under incentive stock programs
Shares: 2025: 295,325; 2024: 1,022,122 	15 	48
Share-based compensation 	120 	117
Issuance of restricted stock awards 	(7) 	(3)
Balance at September 30
Shares: 2025: 1,996,743,794; 2024: 1,991,051,414 	$ 	25,412 $ 	25,020
Common Shares Held in Treasury:
Balance at June 30
Shares: 2025: 255,988,730; 2024: 250,131,563 	$ 	(16,610) $ 	(15,759)
Issued under incentive stock programs
Shares: 2025: 543,100; 2024: 545,287 	36 	35
Purchased
Shares: 2025: 2,425,492; 2024: 7,009,200 	(303) 	(752)
Balance at September 30
Shares: 2025: 257,871,122; 2024: 256,595,476 	$ 	(16,877) $ 	(16,476)
Earnings Employed in the Business:
Balance at June 30 	$ 	48,467 $ 	38,354
Net earnings 	1,644 	1,646
Cash dividends declared on common shares (per share — 2025: $0.59; 2024: $0.55) 	(1,030) 	(958)
Effect of common and treasury share transactions 	22 	14
Balance at September 30 	$ 	49,103 $ 	39,056
Accumulated Other Comprehensive Income (Loss):
Balance at June 30 	$ 	(6,576) $ 	(8,135)
Other comprehensive income (loss) 	(108) 	331
Balance at September 30 	$ 	(6,684) $ 	(7,804)
Noncontrolling Interests in Subsidiaries:
Balance at June 30 	$ 	264 $ 	242
Noncontrolling interests’ share of income, net of distributions and share repurchases 	46 	(10)
Balance at September 30 	$ 	310 $ 	232
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
6

-- 6 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Nine Months Ended September 30
2025 	2024
Common Shares:
Balance at January 1
Shares: 2025:1,991,472,630; 2024: 1,987,883,852 	$ 	25,153 $ 	24,869
Issued under incentive stock programs
Shares: 2025: 5,271,164; 2024: 3,167,562 	290 	148
Share-based compensation 	551 	563
Issuance of restricted stock awards 	(582) 	(560)
Balance at September 30
Shares: 2025: 1,996,743,794; 2024: 1,991,051,414 	$ 	25,412 $ 	25,020
Common Shares Held in Treasury:
Balance at January 1
Shares: 2025: 259,774,639; 2024: 253,807,494 	$ 	(16,844) $ 	(15,981)
Issued under incentive stock programs
Shares: 2025: 4,514,000; 2024: 4,410,852 	295 	279
Purchased
Shares: 2025: 2,610,483; 2024: 7,198,834 	(328) 	(774)
Balance at September 30
Shares: 2025: 257,871,122; 2024: 256,595,476 	$ 	(16,877) $ 	(16,476)
Earnings Employed in the Business:
Balance at January 1 	$ 	47,261 $ 	37,554
Net earnings 	4,748 	4,173
Cash dividends declared on common shares (per share — 2025: $1.77; 2024: $1.65) 	(3,091) 	(2,879)
Effect of common and treasury share transactions 	185 	208
Balance at September 30 	$ 	49,103 $ 	39,056
Accumulated Other Comprehensive Income (Loss):
Balance at January 1 	$ 	(7,906) $ 	(7,839)
Other comprehensive income (loss) 	1,222 	35
Balance at September 30 	$ 	(6,684) $ 	(7,804)
Noncontrolling Interests in Subsidiaries:
Balance at January 1 	$ 	237 $ 	224
Noncontrolling interests’ share of income, net of distributions and share repurchases 	73 	8
Balance at September 30 	$ 	310 $ 	232
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
7

-- 7 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Nine Months Ended September 30
2025 	2024
Cash Flow From (Used in) Operating Activities:
Net earnings 	$ 	4,748 $ 	4,173
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation 	1,064 	998
Amortization of intangible assets 	1,260 	1,413
Share-based compensation 	551 	562
Trade receivables 	(874) 	(533)
Inventories 	(39) 	(293)
Other, net 	(459) 	(630)
Net Cash From Operating Activities 	6,251 	5,690
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(1,482) 	(1,487)
Acquisitions of businesses and technologies, net of cash acquired 	(85) 	—
Proceeds from business dispositions 	— 	1
Sales (purchases) of other investment securities, net 	46 	9
Other 	12 	5
Net Cash From (Used in) Investing Activities 	(1,509) 	(1,472)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other 	(44) 	(126)
Proceeds from issuance of long-term debt 	3 	222
Repayments of long-term debt 	(1,503) 	(20)
Purchases of common shares 	(591) 	(980)
Proceeds from stock options exercised 	391 	239
Dividends paid 	(3,086) 	(2,878)
Other 	(82) 	—
Net Cash From (Used in) Financing Activities 	(4,912) 	(3,543)
Effect of exchange rate changes on cash and cash equivalents 	65 	(13)
Net Increase (Decrease) in Cash and Cash Equivalents 	(105) 	662
Cash and Cash Equivalents, Beginning of Year 	7,616 	6,896
Cash and Cash Equivalents, End of Period 	$ 	7,511 $ 	7,558
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
8

-- 8 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 1 — Basis of Presentation
The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and
Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However,
in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial
position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s
Annual Report on Form 10-K for the year ended December 31, 2024. The condensed consolidated financial statements include the accounts of the parent
company and subsidiaries, after elimination of intercompany transactions.
Note 2 — New Accounting Standards
Recently Adopted Accounting Standards
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures, which expands the breadth and frequency of required segment disclosures. The guidance is
required to be applied retrospectively to all periods presented in the financial statements. Abbott adopted the standard on January 1, 2024. The new
standard did not have an impact on Abbott's consolidated financial statements, but required additional disclosures, retrospectively applied to all periods
presented in Note 14 — Segment Information.
Recent Accounting Standards Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, which requires an entity to disclose on an annual and interim basis, disaggregated information about specific income statement expense
categories. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott
for full year 2027 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to
disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance
should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025
reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
9

-- 9 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 3 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Abbott has four
reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices.
The following tables provide detail by sales category:
Three Months Ended September 30, 2025 	Three Months Ended September 30, 2024
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— $ 	1,097 $ 	1,097 $ 	— $ 	994 $ 	994
Other 	— 	414 	414 	— 	412 	412
Total 	— 	1,511 	1,511 	— 	1,406 	1,406
Nutritional Products —
Pediatric Nutritionals 	520 	457 	977 	568 	387 	955
Adult Nutritionals 	368 	808 	1,176 	382 	729 	1,111
Total 	888 	1,265 	2,153 	950 	1,116 	2,066
Diagnostic Products —
Core Laboratory 	366 	998 	1,364 	332 	982 	1,314
Molecular 	36 	95 	131 	37 	91 	128
Point of Care 	111 	47 	158 	103 	43 	146
Rapid Diagnostics 	373 	227 	600 	560 	264 	824
Total 	886 	1,367 	2,253 	1,032 	1,380 	2,412
Medical Devices —
Rhythm Management 	350 	336 	686 	288 	309 	597
Electrophysiology 	322 	383 	705 	285 	325 	610
Heart Failure 	280 	86 	366 	252 	70 	322
Vascular 	280 	465 	745 	258 	441 	699
Structural Heart 	297 	338 	635 	270 	288 	558
Neuromodulation 	196 	58 	254 	190 	46 	236
Diabetes Care 	796 	1,261 	2,057 	673 	1,052 	1,725
Total 	2,521 	2,927 	5,448 	2,216 	2,531 	4,747
Other 	4 	— 	4 	4 	— 	4
Total 	$ 	4,299 $ 	7,070 $ 	11,369 $ 	4,202 $ 	6,433 $ 	10,635
10

-- 10 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 3 — Revenue (Continued)
Nine Months Ended September 30, 2025 	Nine Months Ended September 30, 2024
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— $ 	3,121 $ 	3,121 $ 	— $ 	2,910 $ 	2,910
Other 	— 	1,033 	1,033 	— 	1,016 	1,016
Total 	— 	4,154 	4,154 	— 	3,926 	3,926
Nutritional Products —
Pediatric Nutritionals 	1,695 	1,377 	3,072 	1,646 	1,377 	3,023
Adult Nutritionals 	1,105 	2,334 	3,439 	1,115 	2,146 	3,261
Total 	2,800 	3,711 	6,511 	2,761 	3,523 	6,284
Diagnostic Products —
Core Laboratory 	1,049 	2,850 	3,899 	969 	2,879 	3,848
Molecular 	111 	265 	376 	112 	272 	384
Point of Care 	315 	133 	448 	308 	133 	441
Rapid Diagnostics 	1,093 	664 	1,757 	1,386 	762 	2,148
Total 	2,568 	3,912 	6,480 	2,775 	4,046 	6,821
Medical Devices —
Rhythm Management 	994 	950 	1,944 	851 	915 	1,766
Electrophysiology 	943 	1,091 	2,034 	841 	983 	1,824
Heart Failure 	824 	249 	1,073 	733 	215 	948
Vascular 	831 	1,381 	2,212 	787 	1,325 	2,112
Structural Heart 	868 	980 	1,848 	761 	876 	1,637
Neuromodulation 	565 	171 	736 	563 	142 	705
Diabetes Care 	2,338 	3,527 	5,865 	1,899 	3,043 	4,942
Total 	7,363 	8,349 	15,712 	6,435 	7,499 	13,934
Other 	12 	— 	12 	11 	— 	11
Total 	$ 	12,743 $ 	20,126 $ 	32,869 $ 	11,982 $ 	18,994 $ 	30,976
Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the third quarter of 2025 and
2024, COVID-19 testing-related sales totaled $69 million and $265 million, respectively. In the first nine months of 2025 and 2024, Abbott’s COVID-19
testing-related sales totaled $208 million and $571 million, respectively.
11

-- 11 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 3 — Revenue (Continued)
Remaining Performance Obligations
As of September 30, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially
unsatisfied) was $6.0 billion in the Diagnostic Products segment and $436 million in the Medical Devices segment. Abbott expects to recognize revenue on
approximately 54 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months
and the remainder thereafter.
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended
warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has
applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance
obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets
primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and
the end of the period, as well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise
primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.
Changes in the contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2024 	$ 	568
Unearned revenue from cash received during the period 	382
Revenue recognized related to contract liability balance 	(300)
Balance at September 30, 2025 	$ 	650
Note 4 — Supplemental Financial Information
Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation
of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating
securities. Net earnings allocated to common shares for the three months ended September 30, 2025, and 2024, were $1.6 billion and for the nine months
ended September 30, 2025, and 2024, were $4.7 billion and $4.2 billion, respectively.
In the second quarter of 2024, Abbott sold a non-core business related to its Established Pharmaceutical Products segment. Abbott recorded a loss of
$143 million on the sale in Other (income) expense, net in its Condensed Consolidated Statement of Earnings. Net assets, which primarily related to
inventory and net property and equipment and had a carrying value of $28 million, were included in the sale. The loss on the sale also included
$116 million of cumulative foreign currency translation adjustment previously recorded in Accumulated other comprehensive income (loss), net of tax.
12

-- 12 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
Other, net in Net Cash From Operating Activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2025 includes $256
million of pension contributions and the payment of cash taxes of $1.5 billion. The first nine months of 2024 included $298 million of pension
contributions and the payment of cash taxes of $1.2 billion.
The following summarizes the activity for the first nine months of 2025 related to the allowance for doubtful accounts as of September 30, 2025:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2024 	$ 	247
Provisions/charges to income 	70
Amounts charged off and other deductions 	(25)
Balance at September 30, 2025 	$ 	292
The Allowance for Doubtful Accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott
considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging
trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-
looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments are as follows:
(in millions) September 30,
2025 December 31,
2024
Long-term Investments:
Equity securities 	$ 	633 $ 	553
Other 	318 	333
Total 	$ 	951 $ 	886
The increase in Abbott’s Long-term Investments as of September 30, 2025, versus the balance as of December 31, 2024, primarily relates to additional
investments and earnings from equity method investments, partially offset by the impairment of certain securities.
Abbott’s equity securities as of September 30, 2025, include $325 million of investments in mutual funds that are held in a rabbi trust. These investments,
which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate
purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of September 30, 2025, with a carrying value of $163 million that are accounted for under the equity method of
accounting and other equity investments with a carrying value of $118 million that do not have a readily determinable fair value.
13

-- 13 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)
The changes in Accumulated other comprehensive income (loss), net of tax, are as follows:
Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024
Balance at June 30 	$ 	(5,955) $ 	(6,926) $ 	(555) $ 	(1,365) $ 	(66) $ 	156
Other comprehensive income (loss) before
reclassifications 	(136) 	497 	(11) 	14 	28 	(148)
Amounts reclassified from accumulated
other comprehensive income 	— 	— 	— 	— 	11 	(32)
Net current period comprehensive income
(loss) 	(136) 	497 	(11) 	14 	39 	(180)
Balance at September 30 	$ 	(6,091) $ 	(6,429) $ 	(566) $ 	(1,351) $ 	(27) $ 	(24)
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024
Balance at January 1 	$ 	(7,505) $ 	(6,504) $ 	(611) $ 	(1,376) $ 	210 $ 	41
Other comprehensive income (loss) before
reclassifications 	1,414 	(41) 	45 	19 	(186) 	(3)
Amounts reclassified from accumulated
other comprehensive income 	— 	116 	— 	6 	(51) 	(62)
Net current period comprehensive income
(loss) 	1,414 	75 	45 	25 	(237) 	(65)
Balance at September 30 	$ 	(6,091) $ 	(6,429) $ 	(566) $ 	(1,351) $ 	(27) $ 	(24)
The reclassification of $116 million out of Accumulated other comprehensive income (loss) in the nine months ended September 30, 2024, is included in
the loss related to the sale of a non-core business included in Other (income) expense, net. Reclassified amounts for cash flow hedges are recorded as Cost
of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 12 — Post-Employment
Benefits for additional details.
Note 6 — Goodwill and Intangible Assets
The total amount of goodwill reported was $24.0 billion at September 30, 2025, and $23.1 billion at December 31, 2024. The amount of goodwill related to
reportable segments at September 30, 2025, was $2.7 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional
Products segment, $3.6 billion for the Diagnostic Products segment, and $17.4 billion for the Medical Devices segment. Foreign currency translation
adjustments increased goodwill by $815 million in the first nine months of 2025. There were no reductions of goodwill relating to impairments in the first
nine months of 2025.
14

-- 14 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 6 — Goodwill and Intangible Assets (Continued)
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion as of September 30, 2025, and $27.1 billion
as of December 31, 2024. Accumulated amortization was $22.8 billion and $21.3 billion as of September 30, 2025, and December 31, 2024, respectively.
In the first nine months of 2025, intangible assets, net of amortization, increased $76 million due to foreign currency translation. Abbott’s estimated annual
amortization expense for intangible assets is approximately $1.7 billion in 2025, $1.5 billion in 2026, $1.2 billion in 2027, $0.7 billion in 2028 and $0.6
billion in 2029.
Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D), were $894 million and $784 million as of September 30,
2025, and December 31, 2024, respectively.
Note 7 — Restructuring Plans
In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical
devices businesses. In the nine months ended September 30, 2025, Abbott recorded employee related severance and other charges of $197 million, of
which $100 million was recorded in Cost of products sold, $38 million was recorded in Research and development, and $59 million was recorded in
Selling, general, and administrative. Payments related to these actions totaled $57 million in the first nine months of 2025 and the remaining liabilities
totaled $140 million at September 30, 2025. In addition, in the first nine months of 2025, Abbott recognized asset impairment charges of $25 million
related to these restructuring plans.
In 2024 and 2023, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices,
diagnostic, nutritional, and established pharmaceutical businesses, including the discontinuation of its ZonePerfect product line in 2024. In addition,
Abbott recognized asset impairment charges of $22 million related to these restructuring plans in the first nine months of 2024. The following summarizes
the activity related to these restructuring actions and the status of the related accruals as of September 30, 2025:
(in millions) 	Total
Accrued balance at December 31, 2024 	$ 	118
Payments and other adjustments 	(69)
Accrued balance at September 30, 2025 	$ 	49
Note 8 — Incentive Stock Programs
In the first nine months of 2025, Abbott granted 1,482,667 stock options, 364,498 restricted stock awards, and 4,397,394 restricted stock units under its
incentive stock program. At September 30, 2025, 51 million shares were reserved for future grants. Information regarding the number of options
outstanding and exercisable at September 30, 2025, is as follows:
Outstanding 	Exercisable
Number of shares 	22,690,333 	19,485,032
Weighted average remaining life (years) 	4.7 	4.1
Weighted average exercise price 	$ 	90.17 $ 	84.79
Aggregate intrinsic value (in millions) 	$ 	995 $ 	958
The total unrecognized share-based compensation cost at September 30, 2025, amounted to $577 million, which is expected to be recognized over the next
three years.
®
15

-- 15 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 9 — Debt and Lines of Credit
On September 15, 2025, Abbott repaid the $500 million outstanding principal amount of its 3.875% Notes upon maturity. On March 17, 2025, Abbott
repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.
Note 10 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates,
primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross
notional amounts totaling $7.2 billion at September 30, 2025, and $7.0 billion at December 31, 2024, are designated as cash flow hedges of the variability
of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2025, will be
included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables
and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the
functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in
exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are
primarily the U.S. dollar and European currencies. At September 30, 2025, and December 31, 2024, Abbott held the gross notional amounts of $12.7
billion and $16.2 billion, respectively, of such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of $619 million and $583 million as of September 30, 2025, and December 31, 2024,
respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign
exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts with a notional amount totaling $1.2 billion at September 30, 2025, and $2.2 billion at December 31, 2024,
to manage its exposure to changes in the fair value of fixed-rate debt. The decrease from December 31, 2024, was due to the maturity of $1.0 billion of
interest rate hedge contracts in conjunction with long-term debt, both of which matured in March 2025. These contracts are designated as fair value hedges
of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-
rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-
rate debt by an offsetting amount.
16

-- 16 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, 2025, and
December 31, 2024:
Fair Value - Assets 	Fair Value - Liabilities
(in millions) September 30,
2025 	December 31, 2024 Balance Sheet Caption September 30,
2025 	December 31, 2024 Balance Sheet Caption
Interest rate swaps designated as fair value
hedges:
Non-current 	$ 	— $ 	— Deferred income
taxes and other assets
$ 	34 $ 	51 Post-employment
obligations, deferred
income taxes and
other long-term
liabilities
Current 	— 	1 Prepaid expenses and
other receivables
— 	— Other accrued
liabilities
Foreign currency forward exchange
contracts:
Hedging instruments 	30 	243 Prepaid expenses and
other receivables 247 	19 Other accrued
liabilities
Others not designated as hedges 	25 	147 Prepaid expenses and
other receivables
57 	112 Other accrued
liabilities
Debt designated as a hedge of net
investment in a foreign subsidiary
— 	— n/a 	619 	583 Long-term debt
$ 	55 $ 	391 	$ 	957 $ 	765
17

-- 17 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative
financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income.
Gain (loss) Recognized in Other Comprehensive Income
(loss) 	Income (expense) and Gain (loss) Reclassified into Income
Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended
September 30,
Nine Months Ended
September 30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Income
Statement
Caption
Foreign currency forward
exchange contracts
designated as cash flow
hedges
$ 	33 $ 	(199) $ 	(270) $ 	39 $ 	(13) $ 	42 $ 	74 $ 	85 Cost of
products sold
Debt designated as a hedge of
net investment in a foreign
subsidiary
16 	(73) 	(36) 	(26) 	— 	— 	— 	— n/a
Interest rate swaps designated
as fair value hedges n/a 	n/a 	n/a 	n/a 	— 	24 	17 	28 Interest
expense
Gains of $9 million and losses of $89 million were recognized in the three months ended September 30, 2025, and 2024, respectively, related to foreign
currency forward exchange contracts not designated as a hedge. Gains of $44 million and $46 million were recognized in the nine months ended
September 30, 2025, and 2024, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported
in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.
The carrying values and fair values of certain financial instruments as of September 30, 2025, and December 31, 2024, are shown in the following table.
The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select
major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.
September 30, 2025 	December 31, 2024
(in millions) 	Carrying Value 	Fair Value 	Carrying Value 	Fair Value
Long-term Investment Securities:
Equity securities 	$ 	633 $ 	633 $ 	553 $ 	553
Other 	318 	318 	333 	333
Total Long-term Debt 	(12,941) 	(12,839) 	(14,125) 	(13,710)
Foreign Currency Forward Exchange Contracts:
Receivable position 	55 	55 	390 	390
(Payable) position 	(304) 	(304) 	(131) 	(131)
Interest Rate Hedge Contracts:
Receivable position 	— 	— 	1 	1
(Payable) position 	(34) 	(34) 	(51) 	(51)
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
18

-- 18 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
Basis of Fair Value Measurement
(in millions) 	Outstanding Balances Quoted Prices in
Active Markets
Significant Other
Observable Inputs
Significant
Unobservable Inputs
September 30, 2025:
Equity securities 	$ 	352 $ 	352 $ 	— $ 	—
Foreign currency forward exchange contracts 	55 	— 	55 	—
Total Assets 	$ 	407 $ 	352 $ 	55 $ 	—
Fair value of hedged long-term debt 	$ 	1,126 $ 	— $ 	1,126 $ 	—
Interest rate swap derivative financial instruments 	34 	— 	34 	—
Foreign currency forward exchange contracts 	304 	— 	304 	—
Contingent consideration related to business combinations 	1 	— 	— 	1
Total Liabilities 	$ 	1,465 $ 	— $ 	1,464 $ 	1
December 31, 2024:
Equity securities 	$ 	323 $ 	323 $ 	— $ 	—
Interest rate swap derivative financial instruments 	1 	— 	1 	—
Foreign currency forward exchange contracts 	390 	— 	390 	—
Total Assets 	$ 	714 $ 	323 $ 	391 $ 	—
Fair value of hedged long-term debt 	$ 	2,096 $ 	— $ 	2,096 $ 	—
Interest rate swap derivative financial instruments 	51 	— 	51 	—
Foreign currency forward exchange contracts 	131 	— 	131 	—
Contingent consideration related to business combinations 	38 	— 	— 	38
Total Liabilities 	$ 	2,316 $ 	— $ 	2,278 $ 	38
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative
instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based
on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on
independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of
contingent consideration from December 31, 2024, reflects a contingent consideration payment related to a previous business combination.
19

-- 19 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 11 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto
Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded
an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is
expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s
milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC) and inadequately warn about the risk of NEC. These lawsuits claim
that certain preterm infants suffered injury or death as a result of contracting NEC. Two cases have gone to trial. In a Missouri state case, a jury awarded a
plaintiff $495 million in damages. In a second Missouri state court case, a jury found in Abbott’s favor, and the judge later ordered a new trial in that
matter. The two Missouri cases are on appeal. In the first three federal Multidistrict Litigation (MDL) “bellwether” cases, the U.S. District Court for the
Northern District of Illinois granted summary judgment in favor of Abbott. The plaintiff in the first case has filed an appeal. Abbott stands by its products
and the information it provided about them. Abbott does not believe that it is probable that a material loss will be incurred related to these lawsuits and
therefore, no reserves have been recorded. Given the uncertainty as to the possible outcome in each of these lawsuits, Abbott is unable to reasonably
estimate a range of possible loss related to these lawsuits.
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental
exposures to be from approximately $5 million to $15 million. The recorded accrual balance at September 30, 2025, for these proceedings and exposures
was approximately $10 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.”
Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the
outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect
on Abbott’s financial position, cash flows, or results of operations, except for the cases discussed in the second paragraph of this note, the resolution of
which could be material to Abbott's financial position, cash flows or results of operations.
Note 12 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are
recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net costs recognized for Abbott’s major defined
benefit plans and post-employment medical and dental benefit plans are as follows:
Defined Benefit Plans 	Medical and Dental Plans
Three Months Ended September
30,
Nine Months Ended September
30,
Three Months Ended September
30,
Nine Months Ended September
30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Service cost - benefits earned during
the period 	$ 	55 $ 	61 $ 	162 $ 	182 $ 	11 $ 	9 $ 	32 $ 	29
Interest cost on projected benefit
obligations 	124 	118 	369 	352 	17 	13 	51 	40
Expected return on plan assets 	(282) 	(263) 	(841) 	(788) 	(7) 	(6) 	(20) 	(18)
Net amortization of:
Actuarial loss, net 	2 	6 	6 	18 	— 	— 	— 	(1)
Prior service cost (credit) 	— 	— 	1 	1 	(2) 	(3) 	(7) 	(10)
Net cost (credit) 	$ 	(101) $ 	(78) $ 	(303) $ 	(235) $ 	19 $ 	13 $ 	56 $ 	40
20

-- 20 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 12 — Post-Employment Benefits (Continued)
Abbott funds its domestic defined benefit plans according to U.S. Internal Revenue Service (IRS) funding limitations. International pension plans are
funded according to similar regulations. In the first nine months of 2025 and 2024, $256 million and $298 million, respectively, were contributed to defined
benefit plans. In the first nine months of 2025 and 2024, $75 million and $28 million were contributed, respectively, to the post-employment medical and
dental plans.
Note 13 — Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2025 and 2024, taxes
on earnings include $91 million and $44 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of
2025, taxes on earnings includes approximately $460 million of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax
benefit in a prior year. In the first nine months of 2025 and 2024, taxes on earnings also included approximately $90 million of net tax benefit and $35
million of net tax expense, respectively, as the result of the resolution of various tax positions related to prior years.
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million.
The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that
were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and
unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the
2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024
with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary
adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and
omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a
deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.
Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process, and/or through
litigation, as necessary. Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues
to believe that its reserves for uncertain tax positions are appropriate.
The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1
proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Pillar 2 proposes to assess a 15 percent
minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt
the Pillar 2 model rules. The enactment of current Pillar 2 model rules did not and is not projected to have a material impact to Abbott's consolidated
financial statements. Abbott continues to monitor the Pillar 1 and Pillar 2 developments.
21

-- 21 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 14 — Segment Information
Abbott’s principal business is the discovery, development, manufacture, and sale of a broad line of healthcare products. Abbott’s products are generally
sold directly to retailers, wholesalers, hospitals, healthcare facilities, laboratories, physicians’ offices, and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing
sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics, and Point of Care Diagnostics
businesses are aggregated and reported as the Diagnostic Products segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care
products. For segment reporting purposes, the Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation, and
Diabetes Care businesses are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are
on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive
Officer (CEO). The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment
operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee
benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible
asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
22

-- 22 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 14 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not
presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
Net Sales to External Customers 	Cost of Products Sold 	Research and Development
Selling, General and
Administrative 	Operating Earnings
Three Months Ended September
30,
Three Months Ended September
30,
Three Months Ended September
30,
Three Months Ended September
30,
Three Months Ended September
30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	1,511 $ 	1,406 $ 	(714) $ 	(644) $ 	(42) $ 	(46) $ 	(364) $ 	(336) $ 	391 $ 	380
Nutritionals 	2,153 	2,066 	(1,223) 	(1,151) 	(55) 	(53) 	(515) 	(550) 	360 	312
Diagnostics 	2,253 	2,412 	(1,290) 	(1,280) 	(150) 	(165) 	(413) 	(409) 	400 	558
Medical Devices 	5,448 	4,747 	(1,767) 	(1,605) 	(462) 	(408) 	(1,390) 	(1,221) 	1,829 	1,513
Total 	$ 	11,365 $ 	10,631 $ 	(4,994) $ 	(4,680) $ 	(709) $ 	(672) $ 	(2,682) $ 	(2,516) $ 	2,980 $ 	2,763
Other 	4 	4
Net sales 	$ 	11,369 $ 	10,635
Corporate functions and plan benefit costs 	(84) 	(140)
Net interest expense 	(44) 	(51)
Share-based compensation (a) 	(120) 	(117)
Amortization of Intangible assets 	(420) 	(470)
Other, net (b) 	(132) 	(45)
Earnings before Taxes 	$ 	2,180 $ 	1,940
Net Sales to External Customers 	Cost of Products Sold 	Research and Development
Selling, General and
Administrative 	Operating Earnings
Nine Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	4,154 $ 	3,926 $ 	(1,914) $ 	(1,819) $ 	(127) $ 	(131) $ 	(1,078) $ 	(1,014) $ 	1,035 $ 	962
Nutritionals 	6,511 	6,284 	(3,502) 	(3,387) 	(161) 	(158) 	(1,676) 	(1,677) 	1,172 	1,062
Diagnostics 	6,480 	6,821 	(3,666) 	(3,671) 	(455) 	(482) 	(1,228) 	(1,206) 	1,131 	1,462
Medical Devices 	15,712 	13,934 	(5,123) 	(4,779) 	(1,293) 	(1,155) 	(4,062) 	(3,620) 	5,234 	4,380
Total 	$ 	32,857 $ 	30,965 $ (14,205) $ (13,656) $ 	(2,036) $ 	(1,926) $ 	(8,044) $ 	(7,517) $ 	8,572 $ 	7,866
Other 	12 	11
Net sales 	$ 	32,869 $ 	30,976
Corporate functions and plan benefit costs 	(177) 	(286)
Net interest expense 	(143) 	(170)
Share-based compensation (a) 	(551) 	(562)
Amortization of Intangible assets 	(1,260) 	(1,413)
Other, net (b) 	(333) 	(452)
Earnings before Taxes 	$ 	6,108 $ 	4,983
______________________________________
(a) 	Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) 	Other, net for the three and nine months ended September 30, 2025 and 2024, includes charges related to restructurings. For the nine months ended September 30, 2025, Other, net
includes a fair value adjustment to a contingent consideration. Other, net for the three and nine months ended September 30, 2024, includes charges related to impairment of IPR&D
and costs related to business integration. Other, net for the nine months ended September 30, 2024, includes a loss on the divestiture of a non-core business.
23

-- 23 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2025
(Unaudited)
Note 14 — Segment Information (Continued)
Depreciation
Additions to
Property and Equipment
Three Months Ended September 30, 	Three Months Ended September 30,
(in millions) 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	28 $ 	23 $ 	38 $ 	52
Nutritionals 	47 	38 	71 	106
Diagnostics 	136 	129 	168 	183
Medical Devices 	97 	87 	140 	151
Total Reportable Segments 	308 	277 	417 	492
Other 	63 	54 	70 	77
Total 	$ 	371 $ 	331 $ 	487 $ 	569
Depreciation
Additions to
Property and Equipment
Nine Months Ended September 30, 	Nine Months Ended September 30,
(in millions) 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	76 $ 	71 $ 	110 $ 	118
Nutritionals 	133 	116 	231 	282
Diagnostics 	397 	387 	469 	475
Medical Devices 	279 	261 	441 	444
Total Reportable Segments 	885 	835 	1,251 	1,319
Other 	179 	163 	192 	194
Total 	$ 	1,064 $ 	998 $ 	1,443 $ 	1,513
Total Assets
(in millions) 	As of September 30, 2025 	As of December 31, 2024
Established Pharmaceuticals 	$ 	3,730 $ 	3,087
Nutritionals 	4,891 	4,404
Diagnostics 	8,201 	7,678
Medical Devices 	10,576 	9,472
Total Reportable Segment Assets 	$ 	27,398 $ 	24,641
Cash and investments 	8,684 	8,853
Goodwill and intangible assets 	29,569 	29,755
All other (c) 	18,530 	18,165
Total Assets 	$ 	84,181 $ 	81,414
(c) 	As of September 30, 2025, and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.
24

-- 24 of 38 --

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Review — Results of Operations
Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Patent protection
and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price
controls, competition, and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and
costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products, and branded generic pharmaceuticals.
The following tables detail sales by reportable segment for the three and nine months ended September 30. Percent changes are versus the prior year and
are based on unrounded numbers.
Net Sales to External Customers
(in millions)
Three Months
Ended
September 30, 2025
Three Months
Ended
September 30, 2024 	Total Change
Impact of Foreign
Exchange
Total Change Excl.
Foreign Exchange
Established Pharmaceutical Products 	$ 	1,511 $ 	1,406 	7.5 % 	0.4 % 	7.1 %
Nutritional Products 	2,153 	2,066 	4.2 	0.2 	4.0
Diagnostic Products 	2,253 	2,412 	(6.6) 	1.2 	(7.8)
Medical Devices 	5,448 	4,747 	14.8 	2.3 	12.5
Total Reportable Segments 	11,365 	10,631 	6.9 	1.4 	5.5
Other 	4 	4 	n/m 	n/m 	n/m
Net Sales 	$ 	11,369 $ 	10,635 	6.9 	1.4 	5.5
Total U.S. 	$ 	4,299 $ 	4,202 	2.3 	— 	2.3
Total International 	$ 	7,070 $ 	6,433 	9.9 	2.3 	7.6
Net Sales to External Customers
(in millions)
Nine Months Ended
September 30, 2025
Nine Months Ended
September 30, 2024 	Total Change
Impact of Foreign
Exchange
Total Change Excl.
Foreign Exchange
Established Pharmaceutical Products 	$ 	4,154 $ 	3,926 	5.8 % 	(1.7)% 	7.5 %
Nutritional Products 	6,511 	6,284 	3.6 	(0.9) 	4.5
Diagnostic Products 	6,480 	6,821 	(5.0) 	(0.2) 	(4.8)
Medical Devices 	15,712 	13,934 	12.8 	0.4 	12.4
Total Reportable Segments 	32,857 	30,965 	6.1 	(0.3) 	6.4
Other 	12 	11 	n/m 	n/m 	n/m
Net Sales 	$ 	32,869 $ 	30,976 	6.1 	(0.3) 	6.4
Total U.S. 	$ 	12,743 $ 	11,982 	6.4 	— 	6.4
Total International 	$ 	20,126 $ 	18,994 	6.0 	(0.4) 	6.4
___________________________________
Notes: 	In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year
average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful
25

-- 25 of 38 --

Table of Contents
The 5.5 percent increase in total net sales during the third quarter of 2025, excluding the impact of foreign exchange, primarily reflected higher product
sales in the Medical Devices and Established Pharmaceutical Products segments. Diagnostic Products sales continued to be impacted by the decline in
COVID-19 testing-related sales and challenging market conditions in China, including the impact of volume-based procurement programs. COVID-19
testing-related sales were $69 million in the third quarter of 2025 compared to $265 million in the third quarter of 2024. Abbott’s net sales were favorably
impacted by changes in foreign exchange rates in the third quarter as the relatively weaker U.S. dollar increased total international sales by 2.3 percent and
total sales by 1.4 percent.
The 6.4 percent increase in total net sales during the first nine months of 2025, excluding the impact of foreign exchange, reflected sales growth in the
Medical Devices and Established Pharmaceutical Products segments, fueled by sales of recently launched products, as well as higher sales of existing
products. Diagnostic Products sales growth continued to be impacted by the decline in COVID-19 testing-related sales and challenging market conditions
in China, including the impact of volume-based procurement programs. COVID-19 testing-related sales totaled $208 million during the first nine months of
2025 and $571 million during the first nine months of 2024. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first
nine months as the relatively stronger U.S. dollar at the beginning of the year decreased total international sales by 0.4 percent and total sales by 0.3
percent.
The table below provides detail by sales category for the nine months ended September 30. Percent changes are versus the prior year and are based on
unrounded numbers.
(in millions) 	September 30, 2025 September 30, 2024 	Total Change
Impact of Foreign
Exchange
Total Change Excl.
Foreign Exchange
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	3,121 $ 	2,910 	7.3 % 	(2.4)% 	9.7 %
Other Emerging Markets 	1,033 	1,016 	1.7 	0.5 	1.2
Nutritional Products —
International Pediatric Nutritionals 	1,377 	1,377 	— 	(1.8) 	1.8
U.S. Pediatric Nutritionals 	1,695 	1,646 	3.0 	— 	3.0
International Adult Nutritionals 	2,334 	2,146 	8.8 	(1.4) 	10.2
U.S. Adult Nutritionals 	1,105 	1,115 	(0.9) 	— 	(0.9)
Diagnostic Products —
Core Laboratory 	3,899 	3,848 	1.3 	(0.3) 	1.6
Molecular 	376 	384 	(2.0) 	— 	(2.0)
Point of Care 	448 	441 	1.7 	(0.1) 	1.8
Rapid Diagnostics 	1,757 	2,148 	(18.2) 	(0.2) 	(18.0)
Medical Devices —
Rhythm Management 	1,944 	1,766 	10.1 	0.4 	9.7
Electrophysiology 	2,034 	1,824 	11.5 	0.2 	11.3
Heart Failure 	1,073 	948 	13.2 	0.3 	12.9
Vascular 	2,212 	2,112 	4.7 	0.1 	4.6
Structural Heart 	1,848 	1,637 	12.9 	0.4 	12.5
Neuromodulation 	736 	705 	4.4 	(0.1) 	4.5
Diabetes Care 	5,865 	4,942 	18.7 	0.6 	18.1
26

-- 26 of 38 --

Table of Contents
In the first nine months of 2025, total Established Pharmaceutical Products sales, excluding the impact of foreign exchange, increased 7.5 percent.
Excluding the unfavorable effect of foreign exchange, sales in Key Emerging Markets for Established Pharmaceutical Products increased 9.7 percent in the
first nine months of 2025, led by higher revenue in several countries and across several therapeutic areas, including cardiometabolic, gastroenterology, and
central nervous system/pain management. Other Emerging Markets, excluding the effect of foreign exchange, increased 1.2 percent in the first nine months
of 2025.
Excluding the impact of foreign exchange, total Nutritional Products sales in the first nine months of 2025 increased 4.5 percent. In U.S. Pediatric
Nutritionals, the 3.0 percent increase in sales in the first nine months of 2025 reflects growth of infant formula and Pedialyte product sales, partially offset
by a decrease in PediaSure product sales. Excluding the effect of foreign exchange, International Pediatric Nutritionals sales increased 1.8 percent in the
first nine months of 2025.
In the first nine months of 2025, U.S. Adult Nutritionals sales decreased 0.9 percent as a result of lower Ensure product sales and the discontinuation of
the ZonePerfect product line in March 2024. In the first nine months of 2025, International Adult Nutritionals sales, excluding the effect of foreign
exchange, increased 10.2 percent due to growth of Ensure and Glucerna product sales.
In the first nine months of 2025, Diagnostic Products sales decreased 4.8 percent, excluding the impact of foreign exchange, and increased 0.6 percent,
excluding the impact of foreign exchange and COVID-19 testing-related sales. In the first nine months of 2025 and 2024, Abbott’s COVID-19 testing-
related sales totaled $208 million and $571 million, respectively.
In Core Laboratory, sales increased 1.6 percent in the first nine months of 2025, excluding the effect of foreign exchange, driven by continued growth of
Alinity product sales outside of China, partially offset by lower sales in China due to the impact of challenging market conditions. In Rapid Diagnostics,
sales decreased 18.0 percent in the first nine months of 2025, excluding the effect of foreign exchange, primarily due to lower demand for COVID-19 tests.
Excluding the effect of foreign exchange, total Medical Devices sales increased 12.4 percent in the first nine months of 2025, led by double-digit growth in
Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology. Higher Diabetes Care sales were driven by continued growth in Abbott's continuous
glucose monitoring (CGM) systems. CGM systems sales totaled $5.6 billion and $4.7 billion in the first nine months of 2025 and 2024, respectively.
Excluding the effect of foreign exchange, CGM systems sales increased 19.4 percent in the first nine months of 2025.
In Heart Failure, the 12.9 percent increase in sales, excluding the effect of foreign exchange, primarily reflects growth in chronic and acute pump products
and related accessories. In Structural Heart, the 12.5 percent increase in sales, excluding the effect of foreign exchange, primarily reflects growth in
TriClip and Navitor products. In Electrophysiology, the 11.3 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher
procedure volumes and increased demand for Abbott's portfolio of products designed to diagnose and treat cardiac arrhythmias. In Rhythm Management,
the 9.7 percent sales increase in the first nine months of 2025, excluding the impact of foreign exchange, was primarily due to growth in Aveir leadless
pacemakers, partially offset by a decrease in traditional pacemaker and implantable cardioverter defibrillator sales.
In March 2025, Abbott obtained CE Mark for its Volt™ Pulsed Field Ablation (PFA) System to treat patients with atrial fibrillation. In May 2025, Abbott
announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system to
treat people with mitral valve disease. In July 2025, Abbott received regulatory approval in Japan for TriClip, a minimally invasive treatment option for
patients with tricuspid regurgitation, or a leaky tricuspid heart valve. In August 2025, Abbott obtained CE Mark for an expanded indication for the
company's Navitor transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or
intermediate risk for open-heart surgery.
®
®
®
®
®
®
® 	®
®
®
27

-- 27 of 38 --

Table of Contents
The gross profit margin percentage was 51.7 percent for the third quarter of 2025, compared to 51.4 percent for the third quarter of 2024, and 52.4 percent
for the first nine months of 2025 compared to 51.0 percent for the first nine months of 2024. The increase in the first nine months of 2025 reflects the
favorable impact of gross margin improvement initiatives, partially offset by higher costs, including tariffs, and the unfavorable impact of foreign
exchange.
Research and development (R&D) expenses increased $53 million to $766 million, or 7.5 percent, in the third quarter of 2025, and increased $112 million
to $2.2 billion, or 5.4 percent, in the first nine months of 2025 compared to the prior year. The increase in R&D expenses in the first nine months of 2025
was primarily driven by higher spending on various projects.
Selling, general, and administrative (SG&A) expenses increased $156 million to $3.1 billion, or 5.4 percent, in the third quarter of 2025, and increased
$413 million to $9.2 billion, or 4.7 percent, in the first nine months of 2025 compared to the prior year due to higher selling and marketing spending to
drive growth across various businesses.
Restructuring Plans
In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical
devices businesses. In the nine months ended September 30, 2025, Abbott recorded employee related severance and other charges of $197 million, of
which $100 million was recorded in Cost of products sold, $38 million was recorded in Research and development, and $59 million was recorded in
Selling, general, and administrative. Payments related to these actions totaled $57 million in the first nine months of 2025 and the remaining liabilities
totaled $140 million at September 30, 2025. In addition, in the first nine months of 2025, Abbott recognized asset impairment charges of $25 million
related to these restructuring plans.
Other (Income) Expense, net
Other (income) expense, net increased from $121 million of income in the third quarter of 2024 to $150 million of income in the third quarter of 2025 and
increased from $222 million of income in the first nine months of 2024 to $414 million of income in the first nine months of 2025. The increase in the third
quarter of 2025 reflects higher income associated with the non-service cost components of net pension and post-retirement medical benefit costs and lower
investment impairments. The increase in the first nine months of 2025 is primarily due to the recognition of a $143 million loss on the sale of a non-core
business related to the Established Pharmaceutical Products segment in the second quarter of 2024. The increase in the first nine months of 2025 also
reflects lower investment impairments and higher income associated with the non-service cost components of net pension and post-retirement medical
benefit costs, partially offset by changes in the fair value of contingent consideration liabilities related to previous business combinations.
Interest Expense, net
Interest expense, net decreased by $7 million to $44 million in the third quarter of 2025 and decreased by $27 million to $143 million in the first nine
months of 2025. In the third quarter and the first nine months of 2025, interest expense decreased primarily as a result of the repayment of long-term debt
in November 2024 and March 2025.
Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2025 and 2024, taxes
on earnings include $91 million and $44 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of
2025, taxes on earnings includes approximately $460 million of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax
benefit in a prior year. In the first nine months of 2025 and 2024, taxes on earnings also included approximately $90 million of net tax benefit and $35
million of net tax expense, respectively, as the result of the resolution of various tax positions related to prior years.
28

-- 28 of 38 --

Table of Contents
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year
in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its
foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments
contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are
erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the
2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024
with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary
adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and
omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a
deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.
Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process, and/or through
litigation, as necessary. Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues
to believe that its reserves for uncertain tax positions are appropriate.
The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1
proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Pillar 2 proposes to assess a 15 percent
minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt
the Pillar 2 model rules. The enactment of current Pillar 2 model rules did not and is not projected to have a material impact to Abbott's consolidated
financial statements. Abbott continues to monitor the Pillar 1 and Pillar 2 developments.
Liquidity and Capital Resources
The decrease in cash and cash equivalents from $7.6 billion at December 31, 2024, to $7.5 billion at September 30, 2025, reflects the repayments of debt in
September and March 2025 of $500 million and $1.0 billion, respectively, and the payment of dividends and capital expenditures in the first nine months of
2025, partially offset by cash generated from operations. Working capital was $10.3 billion at September 30, 2025, and $9.5 billion at December 31, 2024.
The increase in working capital in 2025 primarily reflects increases in trade receivables and inventory.
In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of 2025 totaled $6.3 billion, an
increase of $561 million from the prior year, primarily due to higher segment operating earnings. In the first nine months of 2025, Net cash from operating
activities included $256 million of pension contributions and the payment of cash taxes of $1.5 billion. Net cash from operating activities in the first nine
months of 2024 included $298 million of pension contributions and the payment of cash taxes of $1.2 billion.
At September 30, 2025, Abbott’s long-term debt rating was AA- by S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott expects to
maintain an investment grade rating.
On September 15, 2025, Abbott repaid the $500 million outstanding principal amount of its 3.875% Notes upon maturity. On March 17, 2025, Abbott
repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.
29

-- 29 of 38 --

Table of Contents
In October 2024, the board of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time. This authorization was in
addition to the unused portion of the share repurchase program authorized in December 2021. In the third quarter of 2025, Abbott repurchased 2.4 million
of its common shares for $303 million, which fully utilized the $293 million authorization remaining under the December 2021 share repurchase program,
and a portion of the October 2024 repurchase program.
In each of the first three quarters of 2025, Abbott declared a quarterly dividend of $0.59 per share on its common shares, which represents an increase of
7.3 percent over the $0.55 per share dividend declared in each of the first three quarters of 2024.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue
over the availability, method of delivery, and payment for healthcare products and services. It is not possible to predict the extent to which Abbott or the
healthcare industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1,
Business, and Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2024.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by
Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
30

-- 30 of 38 --

Table of Contents
PART I. FINANCIAL INFORMATION
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Philip P. Boudreau,
evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and
concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose
in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of
1934 (the “Exchange Act”) is recorded, processed, summarized, and reported, within the time periods specified in the Commission’s rules and
forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is
accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate
to allow timely decisions regarding required disclosure.
(b) Changes in internal control over financial reporting. During the quarter ended September 30, 2025, there were no changes in Abbott’s internal
control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to
materially affect, Abbott’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Abbott is involved in various claims, legal proceedings and investigations as described in its Annual Report on Form 10-K for the year ended December
31, 2024 (the “2024 10-K”), including those described below (as of September 30, 2025, except where noted below). While it is not feasible to predict the
outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have
a material adverse effect on Abbott's financial position, cash flows, or results of operations.
In the 2024 Form 10-K, Abbott reported that it is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis as a
result of being administered Abbott’s preterm infant formula products. Abbott further reported in the 2024 10-K that in April 2022, the U.S. Judicial Panel
on Multidistrict Litigation ordered all federal court cases consolidated for pretrial purposes in the U.S. District Court for the Northern District of Illinois.
The U.S. District Court for the Northern District of Illinois granted summary judgment in favor of Abbott in each of the second and third "bellwether"
cases in August and October 2025, respectively.
31

-- 31 of 38 --

Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c) Issuer Purchases of Equity Securities
Period
(a) Total
Number of
Shares (or
Units)
Purchased
(b) Average
Price Paid per
Share (or
Unit)
(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
July 1, 2025 - July 31, 2025 	2,425,000 	$ 	124.76 	2,425,000 $ 	6,990,672,440
August 1, 2025 - August 31, 2025 	— 	— 	— 	6,990,672,440
September 1, 2025 - September 30, 2025 	— 	— 	— 	6,990,672,440
Total 	2,425,000 	$ 	124.76 	2,425,000 $ 	6,990,672,440
____________________________________
1. These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2. On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time (the "2021 Plan"). On October 11, 2024, the board
of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time (the "2024 Plan"). The 2024 Plan was in addition to the unused portion of the 2021
Plan. The amount available for repurchase under the remaining portion of the 2021 Plan has been fully utilized as part of the share repurchases in the third quarter of 2025.
(1) 	(2)
(1) 	(2)
(1) 	(2)
(1) 	(2)
32

-- 32 of 38 --

Table of Contents
Item 6. Exhibits
Exhibit No. 	Exhibit
31.1 	Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2 	Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1 	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
32.2 	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
101 	The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine
months ended September 30, 2025, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed
Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated
Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed
Consolidated Financial Statements.
104 	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit
101).
33

-- 33 of 38 --

Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By: 	/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer
Date: October 29, 2025
34

-- 34 of 38 --

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: October 29, 2025 	/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer

-- 35 of 38 --

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Philip P. Boudreau, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: October 29, 2025 	/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer

-- 36 of 38 --

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2025 as filed
with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer
October 29, 2025
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 37 of 38 --

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2025 as filed
with the Securities and Exchange Commission (the “Report”), I, Philip B. Boudreau, Executive Vice President, Finance and Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer
October 29, 2025
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 38 of 38 --